NASDAQ: BTTX - Better Therapeutics, Inc.

Доходность за полгода: -98.99%
Сектор: Healthcare

График акции Better Therapeutics, Inc.


О компании

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions.

Подробнее
In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

Выручка 1.8E-5
EBITDA -0.0057
Число акций ао 0.02356 млрд
P/BV 3.35
EV/EBITDA -0.7443
Цена ао 0.0137
ISIN US08773T1043
Сайт https://www.bettertx.com
Валюта usd
IPO date 2021-10-28
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Изменение цены за день: 0% (0.0001)
Изменение цены за неделю: 0% (0.0001)
Изменение цены за месяц: 0% (0.0001)
Изменение цены за 3 месяца: -99% (0.01)
Изменение цены за полгода: -98.99% (0.0099)
Изменение цены за год: -99.97% (0.345)
Изменение цены за 3 года: -100% (9.98)
Изменение цены с начала года: -99.95% (0.1943)

Недооценка

Название Значение Оценка
P/S 0 0
P/BV -35.64 0
P/E 0 0
EV/EBITDA -0.8149 0
Итого: 2.5

Эффективность

Название Значение Оценка
ROA, % -107.6 0
ROE, % -221.99 0
Итого: 0

Дивиденды

Название Значение Оценка
Div yield, % 0 0
DSI 0 0
Итого: 0

Долг

Название Значение Оценка
Debt/EBITDA -0.389 10
Итого: 9.8

Импульс роста

Название Значение Оценка
Доходность Revenue, % 0 0
Доходность Ebitda, % 523.39 10
Доходность EPS, % 217.59 10
Итого: 8

Институционалы Объем Доля, %
MMCAP International, Inc. SPC 356270 0.71
Citadel Advisors Llc 216165 0.43
Vanguard Group Inc 198154 0.4
Geode Capital Management, LLC 168821 0.34
Millennium Management LLC 128749 0.26
Blackrock Inc. 88635 0.18
Capital Investment Advisory Services, LLC 71000 0.14
State Street Corporation 58600 0.12
Susquehanna International Group, LLP 38057 0.08
Corient Private Wealth LLC 29180 0.06



Руководитель Должность Оплата Год рождения
Mr. David P. Perry M.B.A. Co-Founder & Executive Chairman 260k 1968 (56 лет)
Mr. Frank L. Karbe CEO, Interim CFO, President & Director 533.37k 1968 (56 лет)
Dr. Mark A. Berman M.D. Chief Medical Officer 573.75k 1976 (48 лет)
Ms. Kristin Wynholds Chief Product Officer 519.07k 1973 (51 год)
Mr. Andres Camacho Senior VP of Technology & Head of Engineering N/A
Ms. Angela Willis Senior Vice President of Market Access N/A
Leslie Miller Controller N/A
Ms. Jessica Meng Chief Commercial Officer N/A

Адрес: United States, San Francisco. CA, 548 Market Street - открыть в Google картах, открыть Яндекс картах
Сайт: https://www.bettertx.com